Business
Board Transition
Board Transition.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 6732A Oxford BioDynamics PLC 31 May 2019 \n\n31 May 2019\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nBoard Transition\nAlison Kibble steps down from OBD Board after 11 years' service\n \nFurther to the announcement of 11 January 2019, Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that Alison Kibble has today stepped down from the Board as Non-Executive Director.\n \nAlison first joined OBD's Board in December 2007 as a representative of the University of Oxford and since the Company's IPO has served as Chair of the Audit Committee and as a member of the Nomination and Remuneration Committees.\n \nFollowing Alison's stepping down, membership of the sub-committees of the Board is as follows:\n \n\n\n\nSub-committee\n\n\nChair\n\n\nOther members\n\n\n\n\nAudit committee\n\n\nDavid Holbrook\n\n\nPeter Pack\n\n\n\n\nNomination committee\n\n\nStephen Diggle\n\n\nDavid Holbrook\nChristian Hoyer Millar\n\n\n\n\nRemuneration committee\n\n\nPeter Pack\n\n\nDavid Holbrook\n\n\n\n \n \nChristian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:\n \n\"On behalf of the Board I would like to thank Alison for her many years of service to OBD. It has been a pleasure to work with her since the Company was spun out of the University of Oxford in 2007. Alison has offered the Executive Directors consistent support and challenge throughout her tenure as a Non-Executive Director, benefiting the Company and its shareholders. We will miss her, and wish her every future success.\"\n \nAlison Kibble added:\n \n\"It has been a real privilege to be part of the team that has seen OBD grow from a small company into a successful listed entity with world-class technology and partnerships with major pharma and institutions. I wish the Board and all the employees well as they take the Company forward into the next exciting phase.\"\n \n-ENDS-\n \nFor further details please contact:\n \n\n\n\nOxford BioDynamics Plc \nChristian Hoyer Millar, CEO \nPaul Stockdale, CFO\n\n\n+44 (0)1865 518910\n\n\...